Key Features
-
Includes both the technical and clinical issues associated with therapeutic drug monitoring.
-
Discusses the utility of therapeutic drug monitoring of newer drugs such as antiretroviral agents, anticonvulsants, antidepressants etc.
-
Provides up-to-date information on issues in pharmacogenomics and personalized medicine with emphasis on therapy with warfarin, certain anticancer drugs and antidepressants.
-
Covers important content on the limitations of commercially available immunoassays (chemical tests) for therapeutic drug monitoring and additional analytical techniques.
Description
Therapeutic Drug Monitoring: Newer Drugs and Biomarkers features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presents new and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists, toxicologists, clinical chemists, laboratory professionals and physicians, this book is an essential resource on the current practice of therapeutic drug monitoring in improving patient safety.
Readership
The primary target market for this book includes clinical pathologists, toxicologists, pharmacologists, laboratory professionals and clinical chemists.
Therapeutic Drug Monitoring, 1st Edition
Chapter 1. Introduction to Therapeutic Drug Monitoring: Frequently and Less Frequently Monitored Drugs
Amitava Dasgupta, Ph.D.
Chapter 2. Effects of Pre-Analytical Variables in Therapeutic Drug Monitoring
Valerie Bush, Ph.D.
Chapter 3. Analytical Techniques used in Therapeutic Drug Monitoring
Michael C. Milone, MD, Ph.D.
Chapter 4. Clinical Utility of Free Drug Monitoring
Marcel Musteata, Ph.D.
Chapter 5. Current Practice of Therapeutic Drug Monitoring: Dose Adjustment of Drugs using Pharmacokinetic models
Franck Saint-Marcoux, Ph.D.
Chapter 6. An Introduction to Personalized Medicine
Annjanette Stone, B.S. and Joshua Bornhorst, Ph.D.
Chapter 7. Application of Ultra-High Throughput Sequencing and Microarray Technologies in Pharmacogenomics Testing
Gary Hardiman, Ph.D.
Chapter 8. Pharmacogenomics and Warfarin therapy
Jenny Martin, PharmD. and Andre Somogyi, PharmD.
Chapter 9. Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection: Example of Antibiotic Therapy Management
Jill Butterfield, PharmD., Thomas P. Lodise, Jr., PharmD., Manjunath P. Pai, PharmD.
Chapter 10. Guidelines for Monitoring of Vancomycin, Aminoglycosides and certain antibiotics
Ronald W. McLawhon, M.D., Ph.D.
Chapter 11. Challenges in Therapeutic Drug Monitoring of Digoxin and other Antiarrhythmic Drugs
Amitava Dasgupta, Ph.D.
Chapter 12. Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants
Matthew Luke, M.D., University of New Mexico. Albuquerque, NM
Chapter 13. Challenges in Therapeutic Drug Monitoring of Classical Tricyclic and Newer Antidepressants: Analytical and Pharmacogenetics Considerations
Uttam Garg, Ph.D. and Angela Ferguson, Ph.D.
Chapter14. Therapeutic Drug Monitoring of Selected Anticancer Drugs: Pharmacogenomics issues
Michael C. Milone, MD, Ph.D.
Chapter 15. Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass Spectrometry
Kathleen A. Kelly, Ph.D. and Anthony W. Butch, Ph.D.
Chapter 16. Biomarkers: The Link between Therapeutic Drug Monitoring and Pharmacodynamics of Immunosuppressants
Michael Oellerich, M.D., Gunnar Brandhorst, M.D., Maria Shipkova, M.D., Eberhard Wieland, M.D.
Chapter 17. Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Infection
Natella Y. Rakhmanina, MD, PhD., Charles J.L. la Porte, PharmD., Ph.D.
Chapter 18. Drug Testing in Pain Management
Roger L. Bertholf, Ph.D., and Gary M. Reisfield, MD
Chapter 19. Role of Therapeutic Drug Monitoring to Identify Clinically Significant Drug-Herbal Supplement Interaction
Alex C. Chin, Ph.D., Leland B. Baskin, M.D.
